AIMS: Literature regarding anticoagulants in older people affected by atrial fibrillation (AF) is limited to retrospective studies, poorly considering the importance of multidimensional frailty. The main objective of this study is to evaluate in hospitalised older persons with AF the benefit/risk ratio of the anticoagulant treatments, considering the severity of frailty, determined by the multidimensional prognostic index (MPI). METHODS: In this European, multicentre, prospective study, older hospitalised patients (≥65 years) with non-valvular AF were followed-up for 12 months. Anticoagulants' use at discharge ascertained using medical records. MPI was calculated using tools derived from comprehensive geriatric assessment, classifying participants in robust, pre-frail or frail. Mortality (primary outcome); vascular events, including ischemic heart disease or ischemic stroke, hemorrhagic stroke or gastrointestinal bleedings (secondary outcomes). RESULTS: 2,022 participants (mean age 82.9 years; females 56.6%) were included. Compared with people not taking anticoagulants (n = 823), people using vitamin K antagonists (n = 450) showed a decreased risk of mortality (hazard ratio, HR = 0.74; 95% CI: 0.59-0.93), more pronounced in patients using direct oral anticoagulants (DOACs) (n = 749) (HR = 0.46; 95% CI: 0.37-0.57). Only people taking DOACs reported a significantly lower risk of vascular events (HR = 0.55; 95% CI: 0.31-0.97). The efficacy of DOACs was present independently from frailty status. The risk of gastrointestinal bleedings and hemorrhagic stroke did not differ based on the anticoagulant treatments and by MPI values. CONCLUSIONS: Anticoagulant treatment, particularly with DOACs, was associated with reduced mortality in older people, without increasing the risk of hemorrhagic events, overall suggesting the importance of treating with anticoagulants older people with AF.

1st Faculty of Medicine Charles University Prague Czech Republic

Ageing Clinical Research Department 2 of Internal Medicine and Center for Molecular Medicine Cologne Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Center for Life Course Health Research University of Oulu Oulu Finland

Department of Interdisciplinary Medicine University of Bari Aldo Moro Bari Italy

Geriatrics Unit Department of Geriatric Care OrthoGeriatrics and Rehabilitation E O Galliera Hospital Genova Italy

Geriatrics Unit Department of Internal Medicine University of Palermo Palermo Italy

National Research Council Neuroscience Section Padova Italy

Servicio de Geriatría Hospital Universitario Ramón y Cajal Madrid Spain

University of Helsinki and Helsinki University Hospital Helsinki Finland

Zobrazit více v PubMed

Zoni-Berisso  M, Lercari  F, Carazza  T, Domenicucci  S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol  2014; 6: 213. PubMed PMC

Polidori  MC, Alves  M, Bahat  G. et al.  Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines. Eur Geriat Med  2021; 13: 5–18. PubMed PMC

Pilotto  A, Veronese  N, Polidori  MC. et al.  The role of prognostic stratification on prescription of anticoagulants in older patients with atrial fibrillation: a multicenter, observational, prospective European study (EUROSAF). Ann Med  2022; 54: 2410–8. PubMed PMC

Caldeira  D, Nunes-Ferreira  A, Rodrigues  R, Vicente  E, Pinto  FJ, Ferreira  JJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr  2019; 81: 209–14. 10.1016/j.archger.2018.12.013. PubMed DOI

Lee  S, Monz  BU, Clemens  A, Brueckmann  M, Lip  GY. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open  2012; 2: e001768. PubMed PMC

Okumura  K, Akao  M, Yoshida  T. et al.  Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med  2020; 383: 1735–45. PubMed

Crome  P, Lally  F, Cherubini  A. et al.  Exclusion of older people from clinical trials. Drugs Aging  2011; 28: 667–77. PubMed

Gill  TM. The central role of prognosis in clinical decision making. JAMA  2012; 307: 199–200. PubMed PMC

Pilotto  A, Ferrucci  L, Franceschi  M. et al.  Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res  2008; 11: 151–61. PubMed PMC

Pilotto  A, Veronese  N, Daragjati  J. et al.  Using the multidimensional prognostic index to predict clinical outcomes of hospitalized older persons: a prospective, multicenter, international study. J Gerontol A  2019; 74: 1643–9. PubMed PMC

Cella  A, Veronese  N, Pomata  M. et al.  Multidimensional frailty predicts mortality better than physical frailty in community-dwelling older people: a five-year longitudinal cohort study. Int J Environ Res Public Health  2021; 18: 12435. 10.3390/ijerph182312435. PubMed DOI PMC

Pilotto  A, Veronese  N, Siri  G. et al.  Association between the multidimensional prognostic index and mortality during 15 years of follow-up in the InCHIANTI study. J Gerontol A  2021; 76: 1678–85. PubMed PMC

Cruz-Jentoft  AJ, Daragjati  J, Fratiglioni  L. et al.  Using the multidimensional prognostic index (MPI) to improve cost-effectiveness of interventions in multimorbid frail older persons: results and final recommendations from the MPI_AGE European Project. Aging Clin Exp Res  2020; 32: 861–8. PubMed

Schäfer  M, Körber  MI, Vimalathasan  R. et al.  Risk stratification of patients undergoing percutaneous repair of mitral and tricuspid valves using a multidimensional geriatric assessment. Circ Cardiovasc Qual Outcomes  2021; 14: e007624. 10.1161/CIRCOUTCOMES.120.007624. PubMed DOI

Pilotto  A, Custodero  C, Maggi  S. et al.  A multidimensional approach to frailty in older people. Ageing Res Rev  2020; 60: 101047. PubMed PMC

Warnier  R, Van Rossum  E, Van Velthuijsen  E. et al.  Validity, reliability and feasibility of tools to identify frail older patients in inpatient hospital care: a systematic review. J Nutr Health Aging  2016; 20: 218–30. PubMed

Pilotto  A, Gallina  P, Copetti  M. et al.  Warfarin treatment and all-cause mortality in community-dwelling older adults with atrial fibrillation: a retrospective observational study. J Am Geriatr Soc  2016; 64: 1416–24. PubMed PMC

Veronese  N, Argusti  A, Canepa  E. et al.  Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF. Eur Geriatr Med  2018; 9: 149–54. PubMed

Bonnekoh  SI, Meyer  AM, Pickert  L. et al.  The multidimensional prognostic index in hospitalized older adults: practicability with regard to time needs. Aging Clin Exp Res  2023; 35: 711–6. PubMed PMC

Kim  DH, Pawar  A, Gagne  JJ. et al.  Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study. Ann Intern Med  2021; 174: 1214–23. PubMed PMC

Kim  D, Yang  P-S, Sung  J-H. et al.  Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke  2022; 53: 1873–82. PubMed

Zeng  S, Zheng  Y, Jiang  J, Ma  J, Zhu  W, Cai  X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med  2022; 24: 1621. PubMed PMC

Chetrit  J, Mendis  N, Afilalo  J. Frailty: as simple as possible, but no simpler. Am Heart Assoc  2021; 14: e008227. PubMed

Lund  J, Saunders  CL, Edwards  D, Mant  J. Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study. Open Heart  2021; 8: e001737. PubMed PMC

McManus  DD, Kiefe  C, Lessard  D. et al.  Geriatric conditions and prescription of vitamin K antagonists vs. direct oral anticoagulants among older patients with atrial fibrillation: SAGE-AF. Front Cardiovasc Med 2019; 6: 155. 10.3389/fcvm.2019.00155. PubMed DOI PMC

Cappato  R, Chiarito  M, Giustozzi  M. et al.  Lower dose direct oral anticoagulants and improved survival: a combined analysis in patients with established atherosclerosis. Eur J Intern Med  2021; 83: 14–20. PubMed

Gadi  I, Fatima  S, Elwakiel  A. et al.  Different DOACs control inflammation in cardiac ischemia-reperfusion differently. Circ Res  2021; 128: 513–29. PubMed PMC

Galyautdinov  G, Feiskhanova  L, Abdullaev  SP. Pleiotropic effects of oral anticoagulants. Russ J Hematol Transfusiol  2019; 64: 90–8.

Ho  P, La Brooy  B, Hayes  L, Lim  WK. Direct Oral Anticoagulants in Frayil Older Adults: A Geriatric Perspective. Seminars in Thrombosis and Hemostasis. 2015; 41: 389–94. PubMed

Mitchell  A, Watson  MC, Welsh  T, McGrogan  A. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med  2019; 8: 554. PubMed PMC